333 related articles for article (PubMed ID: 32107533)
21. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
Garg N; Lavi ES
J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
[TBL] [Abstract][Full Text] [Related]
23. Erdheim-Chester disease.
Starkebaum G; Hendrie P
Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101510. PubMed ID: 32305313
[TBL] [Abstract][Full Text] [Related]
24. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
[TBL] [Abstract][Full Text] [Related]
25. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
Kim S; Lee M; Shin HJ; Lee J; Suh YL
Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
[TBL] [Abstract][Full Text] [Related]
27. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
28. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
29. A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.
Bunaux K; Sevestre H; Emile JF; Capel C; Chenin L; Peltier J
Neurochirurgie; 2018 Dec; 64(6):439-441. PubMed ID: 30274919
[TBL] [Abstract][Full Text] [Related]
30. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
31. Histopathological and Clinical Findings in Cutaneous Manifestation of Erdheim-Chester Disease and Langerhans Cell Histiocytosis Overlap Syndrome Associated With the BRAFV600E Mutation.
Liersch J; Carlson JA; Schaller J
Am J Dermatopathol; 2017 Jul; 39(7):493-503. PubMed ID: 27898473
[TBL] [Abstract][Full Text] [Related]
32. High frequency of clonal hematopoiesis in Erdheim-Chester disease.
Cohen Aubart F; Roos-Weil D; Armand M; Marceau-Renaut A; Emile JF; Duployez N; Charlotte F; Poulain S; Lhote R; Hélias-Rodzewicz Z; Della-Valle V; Bernard O; Maloum K; Nguyen-Khac F; Donadieu J; Amoura Z; Abdel-Wahab O; Haroche J
Blood; 2021 Jan; 137(4):485-492. PubMed ID: 33067622
[TBL] [Abstract][Full Text] [Related]
33. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
36. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
37. Impact of
Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
[TBL] [Abstract][Full Text] [Related]
38. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
39. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
40. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
Kanakis M; Petrou P; Lourida G; Georgalas I
Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
